In this issue:
Everolimus + exemestane in advanced breast cancer
Controversies in anti-EGFR therapy in mCRC
Targeting both HER2 and VEGF in HER2+ MBC
PIK3CA mutations interact with trastuzumab
Infusional high-dose 5FU in stage III CRC
Please login below to download this issue (PDF)